$UCB #UCB S.A. UCB: Bimekizumab: strong efficacy in psoriasis | BUY | EUR102(+16%): UCB - BUY | EUR102(+16%) Bimekizumab: strong efficacy in psoriasis Strong efficacy and clear superiority to Stelara Head-to-head vs Cosentyx to be… https://t.co/8D7j8Dmb1A #equity #stocks https://t.co/ZwfHpQyq61